Omnio Raises €2.9 Million for Wound Treatment Development
Omnio, a biotech company based in Umeå, Sweden, has successfully raised €2.9 million in its latest funding round. The funding comes from existing investors and shareholders, marking a significant step forward for the company as it continues to develop its innovative plasminogen-based therapies aimed at treating chronic wounds.
Focus on Plasminogen Therapy
Omnio is working on developing treatments that leverage plasminogen, a key protein in the body's natural wound-healing process. Chronic wounds, such as diabetic foot ulcers, often fail to heal due to impaired biological processes. Omnio's therapies aim to target these underlying issues, promoting effective healing where traditional methods fall short.
Leadership and Vision
The company was co-founded by Felipe Velasquez, who serves as CEO, and Tor Ny, a founder who also leads Omnio's research and development efforts. Velasquez commented on the recent funding, saying, "This financing demonstrates our continuous progress and strong confidence from our current investors. Their support allows us to continue the development and puts us in a stronger position ahead of our next financing round for clinical studies."
Use of Funds
The newly acquired funds will be directed towards advancing Omnio's plasminogen therapy closer to clinical trials. This is a crucial step in bringing their treatment solutions to the market, potentially offering new hope for patients suffering from chronic wounds.
Looking Ahead
With this funding, Omnio is well-positioned to push forward in its mission to improve wound care through innovative biotechnological solutions. The company's ongoing research and development efforts underscore its commitment to addressing unmet medical needs in wound healing.